• Syntara receives firm commitments to raise approximately A$5.0 million via a two-tranche placement at A$0.028 per share.
  • Funds raised to provide certainty of funding towards completion of the Company’s Phase 2 clinical trials subsequent to the acquiror of the Company’s mannitol business unit (MBU) recently challenging amounts. The total amount currently claimed by Syntara from acquiror (Arna Pharma Pty Ltd) is approximately A$5.1 million.
  • Ongoing and planned clinical trials include myelofibrosis (MF), myelodysplastic syndrome (MDS), skin scarring and iRBD/Parkinson’s disease.
  • Syntara will have a strong post-deal cash balance of approximately A$8.5 million, excluding any amount owed by Arna Pharma Pty Ltd, and expected 2024 R&D tax credit of A$3.6 million.

Read the media announcement here.

Review the Investor Presentation here.

Share

Linkedin
Ask me anything

Submit

Your question will be sent privately to Syntara Therapeutics. The company may choose to make this question public.

Highlights

Subscribe to our news

Subscribe